Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Search
Search
  1. ESMO
  2. Guidelines
  3. ESMO-MCBS

ESMO-MCBS Scorecards

ESMO MCBS 1000x150

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines that have been scored and published by ESMO.

It includes all cancer medicines approved by the European Medicines Agency (from January 2016) and the US Food and Drug Administration (from January 2020).

ESMO-MCBS Scores
Number of studies
Non-curative setting
5 17
4 95
3 125
2 34
1 19
Curative setting
A 38
C 2
ESMO-MCBS Scores by tumour type
Non-curative setting
Breast Cancer 28
Central Nervous System Malignancies 0
Endocrine Tumours 19
Gastrointestinal Cancers 53
Genitourinary Cancers 51
Gynaecological Malignancies 30
Head and neck cancer 6
Refractory NTRK fusion–positive cancers 2
Sarcoma 10
Skin Cancers 24
TMB-H solid tumours 1
Thoracic Malignancies 65
dMMR/MSI-H solid tumours 1
Curative setting
Breast Cancer 8
Central Nervous System Malignancies 1
Endocrine Tumours 0
Gastrointestinal Cancers 15
Genitourinary Cancers 4
Gynaecological Malignancies 0
Head and neck cancer 0
Refractory NTRK fusion–positive cancers 0
Sarcoma 2
Skin Cancers 8
TMB-H solid tumours 0
Thoracic Malignancies 2
dMMR/MSI-H solid tumours 0

The ESMO-MCBS Scorecards

The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.

reset selection
Evaluation form 1 For new approaches to adjuvant therapy or new potentially curative therapies
Evaluation form 2a For therapies that are not likely to be curative with primary endpoint of OS with separate sheets for:
Evaluation form 2b For therapies that are not likely to be curative with primary endpoint PFS with separate sheets for:
Evaluation form 2c  For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies
Evaluation form 3  For single-arm studies in “orphan diseases” and for diseases with “high unmet need” when primary outcome is PFS or ORR.

My watchlist

    Tested Agent(s) Combined Agent(s) Control Arm Treatment Setting Tumour Type Tumour Sub-type Tumour Sub-group Trial Name Ref. Score Scorecard Scorecard
    Pertuzumab Standard adjuvant ChT + 1 year of treatment with trastuzumab Placebo + standard adjuvant ChT + 1 year of treatment with trastuzumab Adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence Breast Cancer Breast Cancer HER2+ APHINITY
    A

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1
    Neratinib - Placebo Extended adjuvant treatment of patients with early-stage hormone receptor-positive HER2-positive breast cancer who completed adjuvant trastuzumab-based therapy <1 year ago Breast Cancer Breast Cancer HR+ HER2+ ExteNET
    A

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1
    Dab/Tram (dabrafenib and trametinib) - Placebo Adjuvant treatment of melanoma after surgical resection. BRAF V600 mutation  Skin Cancers Melanoma BRAF V600E or V600K COMBI-AD
    A

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1
    Pembrolizumab - Placebo Adjuvant treatment of adults with stage III melanoma and lymph node involvement after complete resection Skin Cancers Melanoma - MK-2475-054/4658-MG/KEYNOTE-054
    A

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1
    Nivolumab - Ipilimumab 10mg/kg Adult patients with complete resection of stage IIIB/C or IV melanoma Skin Cancers Melanoma - CheckMate 238
    A

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1
    Imatinib 1-year - Placebo Adjuvant for GIST patients had complete gross resection of a primary gastrointestinal stromal tumour at least 3 cm in size and positive for the KIT protein by immunohistochemistry Sarcoma GIST KIT+ ACOSOG Z9001
    A

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1
    Imatinib 3-years - Imatinib 1-year Adjuvant for high-risk GIST patients with KIT-positive GIST removed at surgery Sarcoma GIST KIT+ SSG XVIII
    A

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1
    Nivolumab Ipilimumab** Placebo Adult patients with resected stage IV melanoma with no-evidence of disease Skin Cancers Melanoma - IMMUNED
    A

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1
    Nivolumab - Placebo Adult patients with resected stage IV melanoma with no-evidence of disease Skin Cancers Melanoma - IMMUNED
    A

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1
    Osimertinib - Placebo Adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations Thoracic Malignancies Non-small-cell Lung Cancer EGFR exon 19 deletions or exon 21 (L858R) mutation ADURA
    A

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    Customise settings

    • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.